FHD-286 + cytarabine

FHD-286 + cytarabine is an investigational combination therapy consisting of **FHD-286**, a potent, selective, orally available, small-molecule allosteric inhibitor of the ATPase subunits BRG1 (SMARCA4) and BRM (SMARCA2) of the SWI/SNF chromatin remodeling complex, and **cytarabine**, a standard cytotoxic antimetabolite chemotherapy. FHD-286 is designed to induce differentiation and anti-tumor activity across a variety of malignancies, especially hematologic cancers such as acute myeloid leukemia (AML)[1][2][3][5]. The rationale for the combination is that FHD-286's mechanism as a broad-based differentiation agent may be enhanced or complemented by the cytoreductive effects of cytarabine in relapsed/refractory AML and myelodysplastic syndromes (MDS)[1][3][5]. This drug is currently being investigated in Phase 1 clinical trials evaluating safety, tolerability, and efficacy in patients with advanced hematologic malignancies[1][3][5].